ACM
EPRS

Asymmetry Capital Management’s EPIRUS BIOPHARMACEUTICALS INC COM EPRS Stock Holding History

Asymmetry Capital Management’s Portfolio EPRS Stock Details EPRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-42,787
Closed -$189K – 27
2015
Q3 		$189K Buy
+42,787
New +$251K 0.42% 22

Other funds holding EPRS

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Asymmetry Capital Management's EPRS Position: Q4 2015 in Review

Asymmetry Capital Management sold out of EPIRUS BIOPHARMACEUTICALS INC COM (EPRS) in Q4 2015, closing a stake of 42,787 shares — an estimated $189K sold.

Asymmetry Capital Management first reported a position in EPRS in Q3 2015 and held it in 1 quarter. The position peaked at $189K in Q3 2015. 45 funds tracked by Wall St. Rank hold EPRS as of Q4 2015.

  • Asymmetry Capital Management reported no remaining EPIRUS BIOPHARMACEUTICALS INC COM position as of Q4 2015 after selling out during the quarter.
  • Asymmetry Capital Management sold 42,787 EPIRUS BIOPHARMACEUTICALS INC COM shares in Q4 2015, an estimated $189K.
  • Asymmetry Capital Management first reported a position in EPIRUS BIOPHARMACEUTICALS INC COM in Q3 2015 and held it in 1 quarter.
  • Asymmetry Capital Management's EPIRUS BIOPHARMACEUTICALS INC COM position peaked at $189K in Q3 2015.
  • 45 funds tracked by Wall St. Rank held EPIRUS BIOPHARMACEUTICALS INC COM as of Q4 2015.

Based on Asymmetry Capital Management's 13F filing for Q4 2015, filed 3 Feb 2016.